A phase III study of EBI-005 in subjects with moderate to severe ocular allergic conjunctivitis

Trial Profile

A phase III study of EBI-005 in subjects with moderate to severe ocular allergic conjunctivitis

Planning
Phase of Trial: Phase III

Latest Information Update: 19 Oct 2015

At a glance

  • Drugs Isunakinra (Primary)
  • Indications Allergic conjunctivitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Oct 2015 New trial record
    • 15 Oct 2015 Eleven intends to initiate this second phase III trial in the second half of 2016 if the results of the first phase III trial are favourable.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top